Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Inhibition of Acute Leukemia By a Small Molecule KYA1797K Which Destabilize RAS and β-Catenin

Seungmin Hahn, MD, Mi Ra Lee, Jungwoo Han, MD PhD, Moon Kyu Kim, Seung-Hwan Oh, Chuhl Joo Lyu, MD PhD

Blood (2019) 134 (Supplement_1): 5758.

https://doi.org/10.1182/blood-2019-126374

Published: 2019

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

EGF Accelerates Hematopoietic Stem Cell Regeneration Following 5-FU Chemotherapy Via G-CSF Receptor Signaling

Sadhna O. Piryani, BS, Angel Y.F. Kam, PhD, Evelyna G. Kliassov, BS, Benny J. Chen, MD, Neil L. Spector, MD, John P. Chute, MD, Nelson J. Chao, MD, Phuong L. Doan, MD

Blood (2016) 128 (22): 1490.

https://doi.org/10.1182/blood.V128.22.1490.1490

Published: 2016

Journal Articles

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Jessica I Hoell, MD, Sebastian Ginzel, MSc, Cornelia Eckert, PhD, Michael Gombert, PhD, Ute Fischer, PhD, Martin Stanulla, MD, Martin Schrappe, MD PhD, Udo zur Stadt, PhD, Peter Bader, MD, Brigitte Strahm, MD, Julia Alten, Anja Moericke, MD, Gabriele Escherich, MD, Arend Stackelberg, MD, Christina Peters, MD, Arndt Borkhardt, MD, Roland Meisel, MD

Blood (2016) 128 (22): 601.

https://doi.org/10.1182/blood.V128.22.601.601

Published: 2016

Journal Articles

Control of Neutrophil Endothelial Transmigration By EC-18 in Chemotherapy Induced Neutropenia

Jae Wha Kim, PhD, Yong-Jae Kim, Young-Jun Kim, PhD, Sun Young Yoon, PhD, Jinseon Jeong, Young-Eun Ko, Su-Hyun Shin, Nina Yoo, Myung-Hwan Kim, MD PhD, Cheolwon Suh, MD PhD, Ki-Young Sohn, Heung-Jae Kim, PhD, Yong-Hae Han, PhD, Saeho Chong, PhD

Blood (2015) 126 (23): 2210.

https://doi.org/10.1182/blood.V126.23.2210.2210

Published: 2015

Journal Articles

Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients

Stephen Sze Yuen Lam, Chae Yin Cher, Nelson Ka Lam Ng, Eric SK Ho, Cheuk Him Man, PhD, Howard CH Chow, Connie J Eaves, Alice MS Cheung, PhD, Anskar Y.H. Leung, MD

Blood (2014) 124 (21): 3624.

https://doi.org/10.1182/blood.V124.21.3624.3624

Published: 2014

Journal Articles

Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib

Debora A Casolari, PhD, Diana G Iarossi, BSc (Hons), Carolyn M Butcher, MMedSc(Hons), Sarah C Bray, PhD, Wendy T Parker, PhD, Chris N Hahn, PhD, Susan Branford, PhD, Peter Bardy, MD, Ian D Lewis, MBBS, PhD, Hamish S Scott, PhD, Steven W Lane, MD PhD, David M Ross, MBBS, PhD FRACP, FRCPA, Richard J D'Andrea, PhD

Blood (2014) 124 (21): 1882.

https://doi.org/10.1182/blood.V124.21.1882.1882

Published: 2014

Journal Articles

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML

Adolfo Diaz Duque, MD, Jasleen Randhawa, MD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Zeev Estrov, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Yesid Alvarado, MD, Varsha Gandhi, PhD, Gautam Borthakur, MD, Jorge E. Cortes

Blood (2014) 124 (21): 3731.

https://doi.org/10.1182/blood.V124.21.3731.3731

Published: 2014

Journal Articles

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Hamid Sayar, MD, MSc, Magdalena Czader, MD, PhD, Chirag Amin, MD, Mary Cangany, Bsc, Larry D Cripe, MD

Blood (2013) 122 (21): 5037.

https://doi.org/10.1182/blood.V122.21.5037.5037

Published: 2013

Journal Articles

Erlotinib Is Not Effective In Patients (Pts) With JAK-2 V617F Positive Polycythemia Vera

Mohamad Cherry, MD, Mohamad Khawandanah, MD, Zhizhuang Joe Zhao, Samer A Srour, MB ChB, Howard Ozer, MD, PhD, George Selby, MD, Bassam Ghabache, MD, Aref Al-Kali, MD

Blood (2013) 122 (21): 1597.

https://doi.org/10.1182/blood.V122.21.1597.1597

Published: 2013

Journal Articles

Identification Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor Sensitivity In Multiple Myeloma

Xing-Ding Zhang, PhD, Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Bart Barlogie, MD, PhD, Saad Z Usmani, MD, FACP, Lin Yang, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 123.

https://doi.org/10.1182/blood.V122.21.123.123

Published: 2013

Journal Articles

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

Sylvain Thepot, Simone Boehrer, MD, Thomas Prebet, Odile Beyne-Rauzy, E. Wattel, MD, Jacques Delaunay, MD, Emmanuel Raffoux, Francois Dreyfus, Stefan Wickenhauser, Mathilde Hunault-Berger, MD, PhD, Fatiha Chermat, Pierre Fenaux, MD, PhD, Lionel Ades, MD, PhD

Blood (2012) 120 (21): 1719.

https://doi.org/10.1182/blood.V120.21.1719.1719

Published: 2012

Journal Articles

A Phase II Clinical Study of Erlotinib for Treatment of Myelodysplastic Syndromes

Rami S. Komrokji, MD, Alan F. List, MD, Daohai Yu, Ph.D, William J Fulp, Yuraima Rodriguez, Pamela S Smith, RN, Jeffrey E. Lancet, MD

Blood (2011) 118 (21): 1714.

https://doi.org/10.1182/blood.V118.21.1714.1714

Published: 2011

Journal Articles

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2790.

https://doi.org/10.1182/blood.V118.21.2790.2790

Published: 2011

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Elodie Lainey, Marie Sebert, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Guido Kroemer, Pierre Fenaux, MD, PhD, Simone Boehrer

Blood (2010) 116 (21): 974.

https://doi.org/10.1182/blood.V116.21.974.974

Published: 2010

Journal Articles

Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study

Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Daohai Yu, Ph.D, Enrique Santana, RN, Lulu Yan, MS, Pamela S Smith, RN, Sara Tinsley, ARNP, Darcie Deaver, ARNP, Ling Zhang, MD, Alan F. List, MD

Blood (2010) 116 (21): 1854.

https://doi.org/10.1182/blood.V116.21.1854.1854

Published: 2010

Journal Articles

Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer

Rachel M Layman, MD, Amy S Ruppert, MAS, Melinda Lynn, RN, BSN, Ewa Mrozek, MD, Bhuvaneswari Ramaswamy, MD, Maryam B Lustberg, MD, Ottman Susan, RN, BSN, Sarah Carothers, MS, Eric H Kraut, MD, Charles L Shapiro, MD

Blood (2010) 116 (21): 1739.

https://doi.org/10.1182/blood.V116.21.1739.1739

Published: 2010

Journal Articles

Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells

Emir Hadzijusufovic, Barbara Peter, Harald Herrmann, Karina Schuch, Tuddow Thaiwong, Vilma Yuzbasiyan-Gurkan, Thomas Rülicke, Winfried Pickl, Michael Willmann, Peter Valent, M.D.

Blood (2010) 116 (21): 4936.

https://doi.org/10.1182/blood.V116.21.4936.4936

Published: 2010

Journal Articles

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Marie Sebert, Elodie Lainey, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2163.

https://doi.org/10.1182/blood.V116.21.2163.2163

Published: 2010

NARROW

Inhibition of Acute Leukemia By a Small Molecule KYA1797K Which Destabilize RAS and β-Catenin

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

EGF Accelerates Hematopoietic Stem Cell Regeneration Following 5-FU Chemotherapy Via G-CSF Receptor Signaling

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Control of Neutrophil Endothelial Transmigration By EC-18 in Chemotherapy Induced Neutropenia

Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients

Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Erlotinib Is Not Effective In Patients (Pts) With JAK-2 V617F Positive Polycythemia Vera

Identification Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor Sensitivity In Multiple Myeloma

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

A Phase II Clinical Study of Erlotinib for Treatment of Myelodysplastic Syndromes

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study

Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer

Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only